Effect of Roxadustat Combined with Erythropoietin in the Treatment of Renal Anemia
Objective:To explore the effect of roxostat combined with erythropoietin in the treatment of renal anemia.Method:A total of 99 hemodialysis patients with renal anemia diagnosed and treated in our hospital from January 2022 to December 2023 were selected as the research objects,and randomly divided into roxadustat group(50 patients)and control group(49 patients).The control group was treated with erythropoietin,and the rosastat group was treated with rosastat combined with erythropoietin.The adverse reactions,red blood cell count(RBC),hematocrit(Hct),serum ferritin content,hemoglobin(Hb)compliance rate,and Hb efficiency were compared between the two groups.Results:There was no significant difference in the incidence of adverse reactions such as hyperkalemia,nausea and vomiting,dizziness and diarrhea between the two groups(P>0.05).The levels of RBC,Hct and serum ferritin in the roxadustat group were higher than those in the control group(P<0.05).After 2 months of treatment,the Hb compliance rate and Hb effective rate in the roxadustat group were 98.00%and 100.00%,respectively,which were higher than 85.71%and 85.71%in the control group(P<0.05).Conclusion:Roxadustat combined with erythropoietin has good safety in the treatment of renal anemia.It can improve the RBC and Hct of patients,increase the serum ferritin content of patients,and improve the Hb compliance rate and Hb efficiency.